![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1567, 2006-01, pp. : 11-12
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Perspectives in therapy for hepatitis C
By Vento Sandro Cainelli Francesca Temesgen Zelalem
Expert Opinion on Investigational Drugs, Vol. 17, Iss. 11, 2008-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
IFN- may prevent HCC recurrence in hepatitis C
Inpharma, Vol. 1, Iss. 1255, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
New horizons in hepatitis C therapy
Inpharma, Vol. 1, Iss. 1265, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Future trends in hepatitis C therapy
By Cornberg Markus Manns Michael
Future Virology, Vol. 1, Iss. 1, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Antiviral therapy reduces HRQOL in patients with hepatitis C
Reactions Weekly, Vol. 1, Iss. 1100, 2006-01 ,pp. :